GHRP-2
Women's HealthCycle-aware, fertility-aware, perimenopause-aware: GHRP-2 is evaluated by women's-health clinicians on multiple axes. Selective ghrelin/GHSR receptor agonist on pituitary somatotrophs Stimulates a pulsatile GH release. Mildly raises ACTH/cortisol and prolactin compared to ipamorelin.. The compound's growth hormone releasing peptide pharmacology produces measurable effects on the systems women's-health practice cares about — cycle regularity, mood, bone density, cardiovascular tone, and the perimenopausal transition. Each is examined in the sections below.
Key Takeaways
Female-physiology lens: GHRP-2 response varies across follicular and luteal phases for premenopausal users; integrates with HRT in perimenopause and postmenopause. Mechanism: Selective ghrelin/GHSR receptor agonist on pituitary somatotrophs. Female monitoring: cycle-day-appropriate estradiol, progesterone, FSH, LH, prolactin, TSH, bone markers; pregnancy contraindication is default. Female dose: 100-300 mcg 2-3x daily subq via subq; cycle-phase tracking for 1-2 cycles. Female-physiology stack partners: Oxytocin, Kisspeptin, GHK-Cu.
Cyclical hormone background shapes how women experience GHRP-2. Selective ghrelin/GHSR receptor agonist on pituitary somatotrophs. Stimulates a pulsatile GH release. Mildly raises ACTH/cortisol and prolactin compared to ipamorelin. For premenopausal users, phase-aware tracking across 1-2 cycles informs the schedule; for perimenopausal users, HRT integration is the dominant question; for postmenopausal users, bone density and cardiovascular tone become the priority considerations.
Perimenopause and menopause integration
For women in the perimenopausal or post-menopausal window, GHRP-2 is most effective when integrated with the broader hormonal picture — HRT (estrogen, progesterone, sometimes testosterone), bone-density support, and cardiometabolic monitoring. Many compounds in this category produce stronger effects in this window precisely because the surrounding hormonal landscape is changing.
Cyclical and hormonal context
Female physiology is cyclical in a way that male physiology is not, and GHRP-2's effects often vary across follicular versus luteal phase. Even where the compound's pharmacology is not directly hormonal, the cyclical hormone background influences how it is metabolised, distributed, and felt. Pre-menopausal users should expect to track response by cycle phase for one or two cycles before settling on a fixed schedule.
Bone density and cardiovascular signalling
Two areas where female physiology diverges sharply post-menopause are bone remodelling and cardiovascular tone. GHRP-2's effect on these systems is one of the underweighted but practically important considerations for women using peptides through the menopausal transition. Bone-marker labs (CTX, P1NP) and cardiovascular indices (lipids, blood pressure, hsCRP) provide a tractable monitoring framework.
For bone density in female users, GHRP-2 is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.
In the perimenopausal window, GHRP-2 for pcos support produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.
Cardiovascular (Female) is one of the dimensions on which women track GHRP-2 response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.
For libido (female) in female users, GHRP-2 is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 100-300 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 60-300 mcg | 4–6 weeks initial cycle |
| Women's Health focus | SubQ | 100-300 mcg | 2-3x daily SubQ |
| Maintenance phase | SubQ | 70-300 mcg | Ongoing with periodic pauses |
Dose timing for GHRP-2 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
GHRP-2 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from women's-health clinicians.
- GHRP-2 + Oxytocin: Activates oxytocin receptors (OXTR) peripherally (uterine smooth muscle, mammary alveoli) and centrally (amygdala, hypothalamus, ventral tegmentum). Pairs naturally with GHRP-2's mechanism in female physiology protocols.
- GHRP-2 + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with GHRP-2's mechanism in female physiology protocols.
- GHRP-2 + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with GHRP-2's mechanism in female physiology protocols.
- GHRP-2 + Epithalon: Identified by Khavinson in St. Pairs naturally with GHRP-2's mechanism in female physiology protocols.
More prolactin/cortisol effect than ipamorelin. Pair with GHRH for synergy.
Lens-specific safety considerations for female physiology use of GHRP-2: More prolactin/cortisol effect than ipamorelin. Pair with GHRH for synergy. Additional female physiology monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| GHRP-2 | Growth hormone releasing peptide | ~15-60 min | Women's Health |
| Oxytocin | Posterior pituitary nonapeptide | ~1-6 min plasma; CNS longer | The 'bonding hormone' — a posterior pituitary nonapeptide with effects on uterine contraction, lactation, and a wide range of social and sexual behaviour via central oxytocin receptors |
| Kisspeptin | Hypothalamic upstream regulator of GnRH | ~28 min IV | The upstream master regulator of GnRH neurons — driving the entire HPG axis from above |
| PT-141 | Melanocortin receptor agonist | ~2-3 hr | An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women |
How will GHRP-2 interact with my cycle?
Can I use GHRP-2 during pregnancy or while trying to conceive?
Can I use GHRP-2 alongside HRT?
Best monitoring labs for female users?
How does GHRP-2's half-life affect dosing?
What is the standard dosing protocol for GHRP-2?
Start a GHRP-2 Protocol
Alukard provides physician-supervised women's health protocols with GMP-certified GHRP-2 and Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.
Get ProtocolQuick Facts
- Molecular weight
- 817 Da
- Sequence length
- 6 aa
- Half-life
- ~15-60 min
- WADA
- Banned (S2)
- FDA
- Approved in Japan for GH stimulation testing only
Stack Partners
All female physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for GHRP-2 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Female Physiology Protocol for GHRP-2
Alukard provides physician-supervised women's health protocols with Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.
HIPAA Compliant · GMP Certified · Physician Supervised